RxDoctor Payments DataLook up a doctor →

Craig Meier, MD

Family Medicine · Omaha, NENPI 1740330745

Payments from drug & device makers

$8,429in general payments, 2019–2025

Across 509 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$1K
  • AstraZeneca$750
  • Novo Nordisk$650
  • Amarin Pharma, Inc.$456
  • Lilly USA, LLC$293
  • plus $4K from 54 others

What the payments were for

  • Food & beverage$8,31599%
  • Education$1131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)105$1,492
Amgen71$1,042
AstraZeneca25$750
Novo Nordisk41$650
Amarin Pharma, Inc.24$456
Lilly USA, LLC22$293
Antares Pharma, Inc.15$273
Pfizer16$246
Bayer15$235
Sanofi-aventis U.S. LLC14$218
Otsuka America Pharmaceutical, Inc.13$216
Novartis11$188
Harmony Biosciences LLC5$135
Merck8$128
Takeda Pharmaceuticals U.S.A., Inc.10$117
Sunovion Pharmaceuticals Inc.8$103
Boehringer Ingelheim7$98
Teva Pharmaceuticals USA, Inc.6$88
Mylan Specialty L.p.5$86
Actelion Pharmaceuticals US, Inc.1$77
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC5$74
Medicure Pharma Inc.1$73
Boston Scientific3$69
Abbott4$64
GSK5$62
Jazz Pharmaceuticals Inc.5$62
Upsher-smith Laboratories LLC3$61
Mannkind Corporation2$61
Esperion Therapeutics, Inc.3$56
Medtronic1$48
Astellas Pharma US Inc3$45
Philips North America LLC2$45
VBI Vaccine (delaware) Inc.3$43
Biohaven Pharmaceuticals, Inc.3$42
Radius Health, Inc.2$37
Dermira, Inc.2$35
Biogen2$35
Grifols USA, LLC2$33
Nalpropion Pharmaceuticals LLC2$30
Seqirus USA Inc1$29
Idorsia Pharmaceuticals US Inc2$29
Pulmonx Corporation1$27
Itamar Medical Inc1$25
Kowa Pharmaceuticals America, Inc.2$25
Biohaven Pharmaceutical Holding Company Ltd.1$25
Ironshore Pharmaceuticals Inc.2$24
Arbor Pharmaceuticals, Inc.1$23
E.r. Squibb & Sons, L.L.C.2$23
Supernus Pharmaceuticals, Inc.1$21
ANI Pharmaceuticals, Inc.1$21
Inspire Medical Systems, Inc.1$20
Azurity Pharmaceuticals, Inc.1$20
Halozyme Inc1$19
Regeneron Healthcare Solutions, Inc.1$19
Genentech USA, Inc.1$18
Exact Sciences1$18
Vertical Pharmaceuticals, LLC1$17
Ultragenyx Pharmaceutical Inc.1$17
Ortho-clinical Diagnostics, Inc.1$16
Sanofi1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,429 in reported general payments places this provider in the 90th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$185,604
Medicare patients
187
Services billed
16,955

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$86,640
JanuviaSitagliptin Phosphate59$44,303
XareltoRivaroxaban36$35,914
ArexvyRsvpref3 Antigen/As01e/Pf80$24,423
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$22,435
RybelsusSemaglutide15$15,176
ShingrixVaricella-Zoster Ge/As01b/Pf67$14,818
MounjaroTirzepatide14$14,679
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$10,724
VascepaIcosapent Ethyl33$10,060
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$9,627
JardianceEmpagliflozin15$8,749
MyrbetriqMirabegron16$8,681
Repatha SyringeEvolocumab13$7,550
Breo ElliptaFluticasone/Vilanterol18$7,225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$246$86,64097 claims
GSKArexvy, Trelegy Ellipta, Shingrix, Anoro Ellipta, Breo Ellipta$62$79,625207 claims
MerckJanuvia$128$44,30359 claims
Novo NordiskRybelsus$650$15,17615 claims
Lilly USA, LLCMounjaro$293$14,67914 claims
AstraZenecaBreztri Aerosphere$750$9,62716 claims
Boehringer IngelheimJardiance$98$8,74915 claims
Astellas Pharma US IncMyrbetriq$45$8,68116 claims
Sanofi-aventis U.S. LLCLantus$218$1,89614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →